Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc reports news on a hub-and-spoke biotherapeutics model built around internal programs and Founded Entities. Recurring updates cover portfolio strategy, annual and half-year results, capital allocation, and clinical development across medicines for inflammatory, immunological, oncologic, gastrointestinal, neurological and neuropsychiatric disorders.
Company news frequently includes deupirfenidone for idiopathic pulmonary fibrosis, LYT-200, a fully human anti-galectin-9 monoclonal antibody for myeloid malignancies, and Seaport Therapeutics programs using the Glyph platform for oral neuropsychiatric medicines. Other developments include scientific publications, clinical data releases, board and leadership changes, shareholder voting matters and capital-structure disclosures tied to PureTech and its Founded Entities.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announces the advancement of LYT-300, an oral allopregnanolone candidate, for treating anxiety disorders and postpartum depression (PPD). A Phase 2a placebo-controlled trial for social anxiety in healthy volunteers will begin in H1 2023, with results expected by year-end. Additionally, an open-label Phase 2a trial for PPD in women is set for H2 2023. Previous Phase 1 results indicated that LYT-300 achieved therapeutic blood levels of allopregnanolone and was well tolerated. This neurosteroid is currently available only as a 60-hour intravenous infusion.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced participation in the SVB Securities Global Biopharma Conference on February 15 at 10:40 am EST. CEO Daphne Zohar and Chief Innovation Officer Eric Elenko will host a fireside chat, which will be accessible via webcast at investors.puretechhealth.com. The company focuses on developing innovative treatments through a pipeline of 26 therapeutics, including FDA-cleared Plenity and EndeavorRx. PureTech aims to transform the treatment of serious diseases, aligning research with clinical insights.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced participation in key investor conferences this January. The William Blair Biotech Private Company Conference will be held on January 30, 2023, featuring a virtual fireside chat at 2:00 PM ET. Subsequently, the SVB Securities Global Biopharma Conference will take place from January 31 to February 2, 2023, offering virtual 1x1 meetings. Vedanta Biosciences focuses on developing oral therapies using defined bacterial consortia to treat conditions like C. difficile infection and inflammatory bowel diseases. The company, founded by PureTech Health, holds 60+ patents and emphasizes microbiome research.
PureTech Health has announced positive topline results from its Phase 1 trial of LYT-300, an oral allopregnanolone therapy aimed at treating neurological conditions. The study demonstrated that LYT-300 achieved therapeutic blood levels of allopregnanolone and engaged GABAA receptors effectively. The therapy was well-tolerated with no severe adverse effects reported. The company plans to present additional trial data in a scientific forum and initiate a Phase 1b/2a trial in the first half of 2023, continuing its focus on innovative biotherapeutics.
PureTech Health will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PST / 5:15 p.m. EST. The presentation will be led by Daphne Zohar, the Founder and CEO of the company. Interested parties can access the webcast at investors.puretechhealth.com. PureTech is a clinical-stage biotherapeutics company focused on advancing treatments for serious diseases. Their pipeline includes 28 therapeutics, including Plenity® and EndeavorRx®, which have received FDA clearance.
PureTech Health plc announced data highlighting LYT-200, a monoclonal antibody targeting galectin-9, as a promising treatment for leukemia. The data, presented at the American Society of Hematology Annual Meeting, suggest significant anti-tumor activity across various leukemia types. A clinical trial evaluating LYT-200 in acute myeloid leukemia (AML) has begun, with results expected in 2023. The company’s ongoing Phase 1 trial has shown safety in escalating doses and effective anti-cancer activity, indicating a potential new therapeutic avenue for patients with poor survival rates.
PureTech Health (LSE:PRTC) announced that its Founded Entity, Sonde Health, has raised $19.25 million in a Series B funding round. This capital will support Sonde's efforts in enhancing its vocal biomarker platform for health monitoring across multiple conditions like asthma and mental health issues. With a total of $35.25 million raised to date, Sonde aims to expand its commercial growth, new health condition applications, and geographical reach, capitalizing on its vast voice dataset of over 1.2 million samples.
PureTech Health has announced the nomination of LYT-310, an oral cannabidiol (CBD) prodrug developed from the Glyph™ platform. LYT-310 shows a three to fourfold increase in oral bioavailability compared to unmodified CBD, which could enhance its therapeutic application across various age groups and indications, including epilepsy. Clinical studies are expected to commence in Q4 2023. This advancement builds on the company's Glyph platform, aimed at improving the oral administration of therapeutics with limited bioavailability.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announced participation in two investor conferences. Management members will engage in fireside chats at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. EST, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 8:50 a.m. EST. The webcasts of these events will be accessible on their investor site. PureTech is focused on innovative biotherapeutics aimed at transforming treatment for serious diseases.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 3:50 PM GMT / 10:50 AM EST. The event will be webcasted, and attendees can access the presentation via the company’s investor relations website. PureTech is focused on innovative therapies to transform treatment for serious diseases, boasting a pipeline of 27 therapeutic candidates, including some with FDA clearance.